opicapone (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Parkinson Disease

Pending FDA approval as an adjunct to levodopa/carbidopa to reduce OFF episodes in patients with Parkinson disease

Next:

Pharmacology

Mechanism of Action

Once daily, peripheral-acting, catechol-O-methyltransferase (COMT) inhibitor; decreases conversion rate of levodopa to 3-O-methyldopa, thereby prolonging levodopa half-life to reduce reducing motor fluctuations

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.